VIFOR-PHARMA-LTD.
Regulatory News:
At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 pandemic and in accordance with Ordinance 3 on measures to combat the coronavirus issued by the Swiss Federal Council, on the basis of Art. 8 of the new COVID-19 Act, shareholders were not permitted to attend the event in person. Shareholders exercised their rights exclusively through the independent proxy and 61.6% of the share capital was represented.
Shareholder approvals
Shareholders approved the Annual Report and the Annual Financial Statements of Vifor Pharma Ltd., as well as the consolidated Financial Statements of Vifor Pharma Group for 2020 by a large majority. The maximum possible 2022 remuneration for the Board of Directors and Executive Committee was also approved, as well as the 2020 Remuneration Report in a consultative vote. In addition, shareholders discharged the members of the Board of Directors and the Executive Committee for the business year 2020. A dividend of CHF 2.00, as proposed by the Board of Directors, was approved and will be paid to shareholders from 12 May 2021 on.
Dr. Alexandre LeBeaut and Åsa Riisberg elected to the Board
The Annual General Meeting confirmed Chairman Jacques Theurillat and the other members of the Board of Directors, Prof. Dr. hon. Michel Burnier, Dr. Romeo Cerutti, Dr. Sue Mahony and Kim Stratton in office.
Dr. Alexandre LeBeaut and Åsa Riisberg were elected as new members of the Board.
As previously announced, Dr. Gianni Zampieri and Gilbert Achermann did not to stand for re-election. The Board of Directors sincerely thanks them for their distinguished services for Vifor Pharma.
Remuneration Committee confirmed
Dr. Sue Mahony (Chairwoman), Prof. Dr. hon. Michel Burnier and Dr. Romeo Cerutti were re-elected to the Remuneration Committee for a term of one year.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005878/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary3.11.2025 03:17:00 CET | Press release
Samsung Epis Holdings to be listed on Korea Exchange (KRX) on November 24, 2025Samsung Epis Holdings to focus on exploring next-generation growth drivers and optimizing business strategies for its subsidiaries ‒Samsung Bioepis and a new company under Samsung Epis HoldingsSamsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings while the new subsidiary company under Samsung Epis Holdings will focus on developing next-generation biotechnology platforms Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings. This press release
Andersen Consulting indgår samarbejde med virksomheden Vivaldi31.10.2025 15:43:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Vivaldi, der er et globalt konsulentfirma inden for forretnings- og brandstrategi, hvilket styrker organisationens løsninger inden for strategi og forretningstransformation. Vivaldi, der blev oprettet i 1999, er kendt for sin tilgang, som forener brand, forretning og teknologi for at hjælpe kunder med at bevare deres position som markedsledere. Med aktiviteter i USA, Europa og Latinamerika samarbejder Vivaldi med nogle af verdens førende virksomheder om at styrke markedspositioner, accelerere innovation og udvikle kundecentrerede forretningsmodeller. I en tid, der er præget af hurtig forandring, drevet af kunstig intelligens, platformdynamikker og kontinuerlig fornyelse, hjælper Vivaldi sine kunder med at gentænke, hvordan forretningsværdi skabes og udnyttes. Virksomhedens tværfaglige teams kombinerer dyb indsigt i forbrugeradfærd og markedsudvikling med strategisk, kreativ og finansiel ekspertise for at levere skræddersyede løsnin
Andersen Consulting styrker sin platform gennem samarbejde med threon31.10.2025 15:35:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for forretningstransformation og digital transformation via en samarbejdsaftale med threon, der er et belgisk konsulentfirma, som er kendt for at levere pragmatisk og helhedsorienteret støtte til strategiimplementering. I mere end 20 år har threon været en vigtig rådgiver for organisationer, der ønsker at omsætte store idéer til reel forretningsmæssig effekt. Virksomheden er specialiseret i strategisk porteføljestyring, digital transformation og ledelsestræning for at hjælpe ledere med at omsætte visioner til konkret handling. threons unikke tilgang kombinerer projektlevering, udvikling af medarbejdere og intelligente softwareløsninger, hvilket giver teams mulighed for at levere hurtigere, opskalere i det rette tempo og opnå varige resultater. Tom Dedecker, CEO for threon, udtalte: "Vi skaber fokus og ro i organisationer, hvilket gør det muligt at træffe hurtigere beslutninger og gennemføre en bæredygtig transformation, der er forankre
SBC Medical to Announce Q3 2025 Financial Results on November 14 and Hold Earnings Call on November 1731.10.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it will release its Q3 2025 financial results on Friday, November 14, 2025, before the U.S. market opens. The Company will hold a Earnings Call on Monday, November 17, 2025 at 5:00 p.m. Eastern Time to discuss the financial results and take questions live. Please register in advance for the conference using the link provided below. https://edge.media-server.com/mmc/p/e2znwqtx It will automatically direct you to the registration page for “SBC Q3 2025 Financial Results Presentation.” Please follow the steps to enter your registration details and click “Submit.” Upon registration, you will be able to access the dedicated conference call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as pas
Motive Brings Seamless eSIM Activation to Luxury European Automotive Brand in Latin America31.10.2025 11:00:00 CET | Press release
Motive, a global leader in connected device lifecycle management and automation, has announced a landmark partnership with a leading operator in Central and South America, bringing seamless and secure mobile connectivity to a luxury European automotive brand’s vehicles in Mexico. The solution—powered by Motive's Entitlement Server—enables the carrier’s subscribers to link their mobile identities directly to their vehicles using embedded SIM (eSIM) technology leveraging GSMA’s mobile connectivity standards. This automotive-first for the Latin America region allows drivers to activate their mobile subscription upon entering a vehicle, delivering a personalized, connected experience on par with their smartphones. Whether for entertainment, navigation, or communication services, users benefit from uninterrupted access to their mobile services with enhanced security and privacy. "This deployment showcases the power of intelligent entitlement and provisioning," said Francisco Viana, VP Sales
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom